Skip to main content
Petros Grivas, MD, Oncology, Seattle, WA

PetrosGrivasMDPhD

Oncology • Seattle, WA

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Medical Director of Genitourinary Cancers Program

Join to view full profile

Dr. Grivas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Grivas' full profile

Already have an account?

  • Office

    825 Eastlake Ave E
    Seattle, WA 98109
    Phone+1 206-520-5000

Summary

  • I am a medical oncologist by training with expertise in genitourinary cancers, such as bladder cancer, prostate cancer and testis cancer. I am dedicated to efficient, personalized and outstanding patient care. I've also had a main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer. In addition, I've spent time giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research.

    • Genomics in urothelial cancer

    Clinical trials in urothelial cancer

Education & Training

  • University of Michigan
    University of MichiganGME Scholars Health Care Administration and Leadership Program, 2012 - 2014
  • University of Michigan
    University of MichiganFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2007 - 2010
  • University of Patras School of Medicine
    University of Patras School of MedicinePh.D., Medical Oncology, 2005 - 2009
  • University of Patras School of Medicine
    University of Patras School of MedicineClass of 2005, M.D.

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2017 - 2026
  • OH State Medical License
    OH State Medical License 2014 - 2019
  • MI State Medical License
    MI State Medical License 2010 - 2017
  • PA State Medical License
    PA State Medical License 2007 - 2010
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Award for Contributions in Cancer Care and Research Athens, Greece, 2018
  • GU Malignancies Pilot Award Case Comprehensive Cancer Center, 2017
  • International Bladder Cancer Network Award IBCN, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference  
    Michael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology
  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma  
    Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine
  • HER-3 in Colorectal Tumourigenesis: From mRNA Levels Through Protein Status to Clinicopathologic Relationships  
    Petros Grivas, MD, European Journal of Cancer
  • Join now to see all

Lectures

  • PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Authored Content

  • HER-3 in Colorectal Tumourigenesis: From mRNA Levels Through Protein Status to Clinicopathologic RelationshipsDecember 2018
  • Recommendations for Follow-up of Muscle-Invasive Bladder Cancer Patients: A Consensus by the International Bladder Cancer NetworkFebruary 2018

Press Mentions

  • Survival Benefit With Durvalumab Should “Immediately” Change Practice in Bladder Cancer, Expert Says
    Survival Benefit With Durvalumab Should “Immediately” Change Practice in Bladder Cancer, Expert SaysSeptember 19th, 2024
  • Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer
    Win for Perioperative Durvalumab in Muscle-Invasive Bladder CancerSeptember 16th, 2024
  • Tip Sheet: The Role of Necrotic Tumor Cores in Metastatic Spread, Why Rural Health Policy Matters — and a Lifetime Achievement Award
    Tip Sheet: The Role of Necrotic Tumor Cores in Metastatic Spread, Why Rural Health Policy Matters — and a Lifetime Achievement AwardMarch 2nd, 2023
  • Join now to see all

Professional Memberships

Other Languages

  • Greek, Italian

Dr. Petros Grivas, Dr. Petros Grivas, MD, Dr. P Grivas